What AMC endocrinology questions test
Endocrinology questions have a recognisable shape. You get a clinical picture, a set of hormone or biochemistry results, and a lead-in asking for the diagnosis, the next test or the treatment. Most marks are won or lost on test logic: knowing which test comes first, which result confirms, and which drugs or conditions make a test unreliable.
Diabetes is the largest single area. It appears in general practice (diagnosis, drug choice, annual review, driving), in emergency medicine (DKA, HHS, hypoglycaemia) and in perioperative care (SGLT2 inhibitors, insulin adjustments). The rest of endocrinology is mostly thyroid, adrenal, pituitary, calcium and bone, with sodium disorders overlapping heavily with nephrology.
Expect to read numbers. TSH and free T4, morning cortisol, aldosterone to renin ratio, calcium with PTH, and HbA1c are all common. Learn the patterns rather than the reference ranges, because stems usually mark results as high, low or normal.
- Diabetes: diagnosis, screening, stepwise drug therapy, complications, sick day rules, driving
- Emergencies: DKA, HHS, hypoglycaemia, adrenal crisis, thyroid storm, severe hypercalcaemia
- Endocrine testing: thyroid, adrenal (Cushing, Addison, aldosterone, phaeochromocytoma), pituitary, calcium and PTH
- Overlap: osteoporosis, obesity, PCOS, male hypogonadism, endocrine causes of hypertension and hyponatraemia
High-yield topic 1: type 2 diabetes diagnosis and management
In Australia, type 2 diabetes can be diagnosed with HbA1c of 6.5% (48 mmol/mol) or more, a fasting plasma glucose of 7.0 mmol/L or more, or a 2-hour glucose of 11.1 mmol/L or more on an oral glucose tolerance test. In an asymptomatic person an abnormal result should be confirmed with a repeat test. HbA1c is unreliable in conditions that change red cell lifespan, such as iron deficiency, haemolysis, haemoglobinopathies, recent transfusion and pregnancy.
Screening uses risk assessment. The RACGP recommends the AUSDRISK tool every three years from age 40, and earlier assessment for Aboriginal and Torres Strait Islander people, who face a much higher risk. People with a high AUSDRISK score, prior gestational diabetes, PCOS with other risk factors or established cardiovascular disease should be tested.
Drug therapy follows the Australian Diabetes Society algorithm. Lifestyle change and metformin are the usual starting point. For people with established cardiovascular disease, heart failure or chronic kidney disease, an SGLT2 inhibitor or GLP-1 receptor agonist with proven benefit is recommended regardless of HbA1c, because it reduces cardiovascular and kidney events. A general HbA1c target of 7% (53 mmol/mol) or below is individualised: tighter for younger, healthy patients and looser for frail older people or those prone to hypoglycaemia.
Annual review covers HbA1c, blood pressure, lipids, absolute CVD risk, kidney health (eGFR and urine albumin-to-creatinine ratio), eye screening, foot assessment and vaccination. Sulfonylureas and insulin cause hypoglycaemia and weight gain; metformin is held when eGFR is severely reduced or during acute illness with dehydration.
- HbA1c 6.8% in an asymptomatic person: repeat to confirm before diagnosis
- Type 2 diabetes plus prior MI: add an SGLT2 inhibitor or GLP-1 RA with cardiovascular benefit
- Type 2 diabetes plus albuminuria: SGLT2 inhibitor and ACE inhibitor or ARB for kidney protection
- Sick day rules: hold metformin and SGLT2 inhibitors during dehydrating illness; check ketones on SGLT2 inhibitors
- Driving with insulin or sulfonylureas: check glucose before driving; Diabetes Australia teaches above 5 to drive
High-yield topic 2: type 1 diabetes, DKA, HHS and hypoglycaemia
Type 1 diabetes can present at any age, including in adults, and may be misread as type 2. Clues are rapid weight loss, ketosis, a lean build and other autoimmune disease. Islet antibodies such as GAD support the diagnosis. Insulin is always required. Continuous glucose monitoring is subsidised for people with type 1 diabetes through the NDSS in Australia.
DKA is diagnosed by raised glucose, ketonaemia (blood ketones usually 3 mmol/L or more) and metabolic acidosis (pH below 7.3 or bicarbonate below 15 mmol/L). Treatment priorities are fluid resuscitation with crystalloid, a fixed-rate insulin infusion, close potassium monitoring and replacement, and finding the trigger. Potassium falls as insulin drives it into cells, so check it before and during insulin; if potassium is low, replace it before starting insulin. Add dextrose once glucose falls while continuing insulin to clear ketones.
Euglycaemic DKA is a key modern trap. Patients taking an SGLT2 inhibitor can develop DKA with glucose only mildly raised or even normal, especially after surgery, fasting, acute illness, or very low carbohydrate diets. The Australian Diabetes Society and ANZCA advise withholding SGLT2 inhibitors before surgery and procedures that require fasting. Any unwell patient on an SGLT2 inhibitor needs blood ketones checked, whatever the glucose.
HHS occurs mostly in older people with type 2 diabetes: very high glucose, marked dehydration and high osmolality without significant ketoacidosis. Fluid replacement is the main treatment, given more cautiously, with insulin added once glucose stops falling with fluids alone. Hypoglycaemia is treated with fast-acting carbohydrate if the patient can swallow, followed by longer-acting carbohydrate; if not, IV glucose or IM glucagon.
- Unwell, on SGLT2 inhibitor, glucose 9 mmol/L, acidotic: euglycaemic DKA until proven otherwise
- DKA with potassium below the safe range: replace potassium before insulin
- HHS: correct fluids and sodium slowly to avoid cerebral oedema
- Recurrent hypoglycaemia: review insulin or sulfonylurea dose, renal function, alcohol and hypoglycaemia awareness
High-yield topic 3: thyroid, adrenal and pituitary
For thyroid questions, TSH is the first test. Low TSH with high free T4 or T3 is hyperthyroidism; Graves disease (diffuse goitre, eye signs, TSH receptor antibodies), toxic nodular goitre and thyroiditis are the usual causes, and a nuclear uptake scan separates them when needed. High TSH with low free T4 is primary hypothyroidism, usually Hashimoto thyroiditis in Australia; treat with levothyroxine and recheck TSH after about six weeks. Low TSH with low free T4 suggests a pituitary cause or non-thyroidal illness. Subclinical hypothyroidism is often monitored rather than treated, unless TSH is markedly raised, the patient is pregnant or planning pregnancy, or symptoms are clear.
A thyroid nodule is assessed with TSH and ultrasound; fine needle aspiration depends on ultrasound features and size. Amiodarone can cause both hypo- and hyperthyroidism. In pregnancy, untreated hypothyroidism affects the fetus, and levothyroxine dose usually needs increasing.
Adrenal insufficiency presents with fatigue, weight loss, hypotension, hyponatraemia and hyperkalaemia, and pigmentation in primary disease. Adrenal crisis is an emergency: give IV hydrocortisone immediately and IV fluids, and do not delay treatment for test results. Patients on long-term steroids risk adrenal crisis if they stop suddenly or are acutely unwell, so they need sick day steroid advice.
For Cushing syndrome, first exclude exogenous steroids, then use a screening test such as the overnight dexamethasone suppression test, 24-hour urinary free cortisol or late-night salivary cortisol. Prolactinoma presents with galactorrhoea, menstrual change or erectile dysfunction, and is usually treated first with a dopamine agonist such as cabergoline. Always check for drugs that raise prolactin, especially antipsychotics and metoclopramide. A pituitary mass with bitemporal hemianopia needs urgent assessment.
- Suspected adrenal crisis: IV hydrocortisone now, tests later
- Low TSH and new AF in an older patient: check free T4 and T3; treat the thyroid cause
- Raised prolactin on an antipsychotic: think drug cause before ordering a pituitary MRI
- Sudden headache and visual loss with a known pituitary tumour: pituitary apoplexy, steroids and urgent imaging
High-yield topic 4: calcium, bone, obesity, PCOS and endocrine hypertension
Hypercalcaemia questions start with PTH. A raised or inappropriately normal PTH with high calcium means primary hyperparathyroidism, the commonest cause in outpatients. A suppressed PTH means a PTH-independent cause, most often malignancy in hospitalised patients, but also vitamin D excess, granulomatous disease such as sarcoidosis, and thiazides. Severe symptomatic hypercalcaemia is treated with IV saline rehydration and then an IV bisphosphonate. Hypocalcaemia after thyroid or parathyroid surgery is a classic post-operative question; perioral tingling and carpopedal spasm are early signs.
Osteoporosis is diagnosed by a minimal trauma fracture or a DXA T-score of -2.5 or lower. Exclude secondary causes (vitamin D deficiency, coeliac disease, hyperthyroidism, hyperparathyroidism, glucocorticoids, hypogonadism, myeloma). Treatment usually starts with an oral bisphosphonate or denosumab, with calcium and vitamin D sufficiency. PBS access to anti-osteoporosis medicines depends on criteria such as a minimal trauma fracture or a low T-score with age requirements. Denosumab must not be stopped without follow-on treatment, because rebound vertebral fractures can occur.
Obesity management in Australia combines lifestyle change, pharmacotherapy (including GLP-1 receptor agonists), and bariatric surgery for selected patients. PCOS is diagnosed with the Rotterdam criteria as applied in the International Evidence-based Guideline for PCOS, which was led from Australia; it carries a higher risk of type 2 diabetes, so glucose screening is recommended. Male hypogonadism needs two morning fasting testosterone levels and LH and FSH; testosterone is avoided in men who want fertility because it suppresses sperm production.
Endocrine hypertension is examined through primary aldosteronism (hypertension with or without hypokalaemia; screen with the aldosterone to renin ratio, noting interfering drugs), phaeochromocytoma (episodic headache, sweating and palpitations; plasma metanephrines) and Cushing syndrome.
- High calcium, high PTH, well outpatient: primary hyperparathyroidism
- High calcium, suppressed PTH, weight loss, smoker: malignancy
- Young adult with resistant hypertension and low potassium: aldosterone to renin ratio
- Woman with PCOS: screen for glucose intolerance and cardiovascular risk
Australian practice differences that change the answer
Endocrine biology is universal, but screening, drug access and safety rules are local. The AMC tests them because they decide what an Australian doctor actually does.
- Diagnosis: HbA1c of 6.5% or more is accepted for diagnosing type 2 diabetes, with a repeat test in asymptomatic people
- Screening: AUSDRISK every three years from age 40; earlier assessment for Aboriginal and Torres Strait Islander people
- Drug choice: ADS algorithm places SGLT2 inhibitors and GLP-1 RAs early for CVD, HF and CKD; PBS criteria affect what can be prescribed
- Perioperative: ADS and ANZCA guidance to withhold SGLT2 inhibitors before surgery and fasting procedures
- Driving: Austroads standards for diabetes, including hypoglycaemia awareness and commercial driver rules
- Supplies: NDSS provides subsidised products, including CGM for people with type 1 diabetes
- PCOS: the International Evidence-based Guideline, led by Australian researchers, is the reference
How to approach endocrine stems
First decide whether the patient is in an endocrine emergency. Hypotension with hyponatraemia and hyperkalaemia suggests adrenal crisis. Acidosis with ketones suggests DKA, even if glucose is normal. Confusion with severe hypercalcaemia needs fluids. Emergencies are treated before the diagnosis is confirmed.
If the patient is stable, look at the results and name the axis: high or low hormone, high or low controlling hormone. A raised hormone with suppressed controller means a primary problem; both raised or both low suggests a central problem. Then check the medication list. Steroids, amiodarone, lithium, antipsychotics, thiazides and biotin supplements all distort endocrine results.
Finally, pick the simplest confirming test. The AMC prefers the logical next step, not the most advanced one. A raised calcium needs a PTH before any scan. A low TSH needs free T4 and T3 before an uptake scan.
- Read the drug list before the results
- Emergency first, diagnosis second
- Screen, then confirm, then localise: imaging comes after biochemistry
| Results or presentation | Most likely diagnosis | Next step |
|---|---|---|
| HbA1c 7.1%, asymptomatic, age 52 | Probable type 2 diabetes | Repeat test to confirm, then lifestyle and metformin |
| On SGLT2 inhibitor, vomiting, glucose 10, pH 7.18 | Euglycaemic DKA | Stop SGLT2 inhibitor, fluids, insulin with dextrose |
| Glucose 45, osmolality very high, no ketosis, age 80 | HHS | Careful IV fluids, then insulin if needed |
| Low TSH, high free T4, eye signs | Graves disease | TSH receptor antibodies; antithyroid drug |
| High TSH, low free T4 | Primary hypothyroidism | Levothyroxine; recheck TSH in about 6 weeks |
| Hypotension, low sodium, high potassium, pigmentation | Adrenal crisis | IV hydrocortisone and fluids immediately |
| High calcium, high PTH | Primary hyperparathyroidism | Check vitamin D and renal function; surgical referral if criteria met |
| High calcium, suppressed PTH, weight loss | Malignancy-related hypercalcaemia | IV saline then IV bisphosphonate; find the cancer |
| Hypertension with low potassium | Primary aldosteronism | Aldosterone to renin ratio |
| Galactorrhoea on risperidone | Drug-induced hyperprolactinaemia | Review the drug before pituitary imaging |
Worked examples in AMC style
Pick an answer to see why each option is right or wrong. These examples are written for this page; the bank holds the full set for endocrinology & diabetes.
Example 1
A 58-year-old man with type 2 diabetes is admitted two days after a laparoscopic cholecystectomy with nausea, vomiting and abdominal pain. He takes metformin and empagliflozin, which were continued until surgery. His blood glucose is 9.8 mmol/L, venous pH 7.19, bicarbonate 11 mmol/L and blood ketones 5.2 mmol/L.
What is the most likely diagnosis?
-
Metformin-associated lactic acidosis is possible but the high ketone level explains the acidosis.
-
A bile leak may cause pain and sepsis, but it would not produce ketones of 5.2 mmol/L with a near-normal glucose.
-
HHS has very high glucose and osmolality without significant ketoacidosis, the opposite of this picture.
-
Correct. Ketoacidosis with only mildly raised glucose in a patient on an SGLT2 inhibitor around surgery is euglycaemic DKA. It needs insulin with dextrose and fluids, and the SGLT2 inhibitor stopped.
-
Starvation ketosis causes mild ketosis, not severe acidosis with a bicarbonate of 11.
Show answer and reasoning
Answer: D. Euglycaemic diabetic ketoacidosis
- A. Metformin-associated lactic acidosis is possible but the high ketone level explains the acidosis.
- B. A bile leak may cause pain and sepsis, but it would not produce ketones of 5.2 mmol/L with a near-normal glucose.
- C. HHS has very high glucose and osmolality without significant ketoacidosis, the opposite of this picture.
- D. Correct. Ketoacidosis with only mildly raised glucose in a patient on an SGLT2 inhibitor around surgery is euglycaemic DKA. It needs insulin with dextrose and fluids, and the SGLT2 inhibitor stopped.
- E. Starvation ketosis causes mild ketosis, not severe acidosis with a bicarbonate of 11.
Unwell on an SGLT2 inhibitor: check ketones; normal glucose does not exclude DKA.
Based on: ADS/ANZCA perioperative guidance on SGLT2 inhibitors and euglycaemic ketoacidosis
Example 2
A 34-year-old woman is brought to the emergency department with vomiting, abdominal pain and dizziness. She has lost weight over several months and has darker skin creases. BP is 78/44 mmHg. Sodium is 124 mmol/L, potassium 6.1 mmol/L and glucose 3.4 mmol/L. A random cortisol has been sent.
What is the most appropriate immediate management?
-
Adrenal crisis can be fatal within hours. Treatment must not wait for confirmation.
-
A Synacthen test confirms adrenal insufficiency later. It is not the immediate step in a shocked patient.
-
Correct. Hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia and pigmentation suggest primary adrenal crisis. IV hydrocortisone and fluids are given at once.
-
Fludrocortisone is long-term mineralocorticoid replacement. It is not adequate in crisis.
-
The potassium will improve with hydrocortisone and fluids. Insulin risks worsening her hypoglycaemia.
Show answer and reasoning
Answer: C. Give IV hydrocortisone and IV saline immediately
- A. Adrenal crisis can be fatal within hours. Treatment must not wait for confirmation.
- B. A Synacthen test confirms adrenal insufficiency later. It is not the immediate step in a shocked patient.
- C. Correct. Hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia and pigmentation suggest primary adrenal crisis. IV hydrocortisone and fluids are given at once.
- D. Fludrocortisone is long-term mineralocorticoid replacement. It is not adequate in crisis.
- E. The potassium will improve with hydrocortisone and fluids. Insulin risks worsening her hypoglycaemia.
Suspected adrenal crisis: give IV hydrocortisone and fluids first, confirm later.
Based on: Therapeutic Guidelines: Endocrinology
Example 3
A 62-year-old woman sees her GP for review of type 2 diabetes diagnosed four years ago. She had a myocardial infarction last year. She takes metformin, a statin, aspirin and ramipril. Her HbA1c is 7.0% (53 mmol/mol) and eGFR 68 mL/min/1.73 m2. She has no hypoglycaemia. Her BMI is 31 kg/m2.
What is the most appropriate change to her diabetes treatment?
-
Her glucose is at target, but the guideline recommends a drug with proven cardiovascular benefit in established CVD regardless of HbA1c.
-
Sulfonylureas lower glucose but do not reduce cardiovascular events and cause weight gain and hypoglycaemia.
-
Correct. With established cardiovascular disease, the ADS algorithm recommends an SGLT2 inhibitor or GLP-1 receptor agonist with cardiovascular benefit, independent of HbA1c.
-
Insulin is not needed at this HbA1c and causes weight gain and hypoglycaemia.
-
Metformin is working and well tolerated. DPP-4 inhibitors have not shown cardiovascular benefit.
Show answer and reasoning
Answer: C. Add an SGLT2 inhibitor for cardiovascular benefit
- A. Her glucose is at target, but the guideline recommends a drug with proven cardiovascular benefit in established CVD regardless of HbA1c.
- B. Sulfonylureas lower glucose but do not reduce cardiovascular events and cause weight gain and hypoglycaemia.
- C. Correct. With established cardiovascular disease, the ADS algorithm recommends an SGLT2 inhibitor or GLP-1 receptor agonist with cardiovascular benefit, independent of HbA1c.
- D. Insulin is not needed at this HbA1c and causes weight gain and hypoglycaemia.
- E. Metformin is working and well tolerated. DPP-4 inhibitors have not shown cardiovascular benefit.
Type 2 diabetes with CVD, HF or CKD: add SGLT2i or GLP-1 RA whatever the HbA1c.
Based on: ADS Australian Type 2 Diabetes Glycaemic Management Algorithm; RACGP Management of type 2 diabetes
Quick recall
Tap a card to turn it over. If you can answer all eight without looking, move on to timed questions.
Where candidates lose marks
- Normal glucose equals no DKA
SGLT2 inhibitors can cause euglycaemic DKA. Always check ketones in unwell patients taking them.
- Waiting for cortisol
In suspected adrenal crisis, hydrocortisone comes first. Delay can be fatal.
- Treating HbA1c only
In established CVD or CKD the drug choice is about organ protection, not just glucose.
- Imaging before biochemistry
Pituitary, adrenal and parathyroid scans come after the hormone diagnosis. Incidentalomas are common.
- Ignoring drug causes
Antipsychotics raise prolactin, amiodarone and lithium affect thyroid, and steroids cause Cushing features. Read the drug list.
How to study endocrinology & diabetes
Day 1: Type 2 diabetes. Diagnosis thresholds, AUSDRISK, ADS algorithm, annual review and sick day rules.
Day 2: Type 1 diabetes and emergencies. DKA steps, euglycaemic DKA, HHS and hypoglycaemia, plus driving rules.
Day 3: Thyroid. TSH-first logic, hyper- and hypothyroidism causes, nodules, amiodarone and pregnancy.
Day 4: Adrenal and pituitary. Adrenal crisis, Cushing screening, primary aldosteronism, phaeochromocytoma, prolactinoma.
Day 5: Calcium and bone, obesity, PCOS and male hypogonadism, then 25 mixed bank questions.
Day 6: Timed block of 40 endocrine questions. For each miss, note whether it was test logic, a drug effect or an emergency step.
Sources and further reading
Check the current edition of each guideline before your exam. This page is study material, not clinical advice.
- Australian Diabetes Society: Australian Type 2 Diabetes Glycaemic Management Algorithm
- RACGP: Management of type 2 diabetes: A handbook for general practice
- Therapeutic Guidelines: Diabetes and Endocrinology
- Diabetes Australia and the National Diabetes Services Scheme (NDSS)
- Healthy Bones Australia and RACGP osteoporosis guidance
- International Evidence-based Guideline for the Assessment and Management of PCOS (Monash University)
- Austroads: Assessing Fitness to Drive